

CFSE Cell Division Tracker Kit

Catalog# / Size	423801 / 1 kit
Regulatory Status	RUO
Other Names	5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester Kit, CFDA SE Kit
Description	CFSE Cell Division Tracker Kit is composed of 5 vials, 100 µg per vial of CFSE (formally known as 5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester of CFDA SE), and 500 µl of anhydrous DMSO. CFSE is able to passively diffuse into cells. Inside the cell, its acetate groups are cleaved by intracellular esterases, and the molecules are converted to fluorescent esters. CFSE is retained within the cell and covalently couples to intracellular molecules via its succinimidyl group. Due to this covalent coupling reaction, fluorescent CFSE can be retained within the cell for an extremely long period. Also, due to this stable linkage, once the dye has been incorporated within the cell, it is not transferred to adjacent cells. CFSE is widely used for cell proliferation assays and <i>in vivo</i> cell tracking.

Product Details

Preparation	The CFSE Cell Division Tracker Kit is composed of lyophilized CFSE and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 36 µl of DMSO to one vial of CFSE dye until fully dissolved.
Storage & Handling	Store CFSE Cell Division Tracker Kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the CFSE, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application	ICFC - Quality tested In vivo cell tracking¹ - Reported in the literature, not verified in house
Recommended Usage	This lot has been tested by flow cytometric analysis of <i>in vitro</i> cell proliferation assay. It can be used at concentrations ranging from 0.5 - 10 µM for cell labeling. It is recommended that the reagent be titrated for optimal performance for each cell type, culturing condition, or application.
Application Notes	The molecular weight of CFSE is 557.47. The excitation and emission wavelengths of CFSE-labeled cells are 492 nm and 517 nm, respectively. Each 100 µg vial of CFSE may be reconstituted with 36 µl of anhydrous DMSO to yield a stock concentration of 5 mM. Materials Provided: 5 vials x 100 µg CFSE 500 µl anhydrous DMSO CFSE Labeling Procedure: 1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrifuge to ensure the reagent is at the bottom of the vial. 2. Prepare stock solution by reconstituting 1 vial of lyophilized CFSE dye in 36 µL of DMSO to make a 5 mM solution. 3. Prepare a 5 µM working solution by diluting 1 µL of 5 mM CFSE stock solution in 1 mL PBS for every 1 mL of cell suspension (or at an optimal working concentration as determined by titration). 4. Spin down and resuspend cells at 10-100 x 10⁶ cells/mL in the CFSE working solution. 5. Incubate cells for 20 minutes at room temperature or 37°C and keep protected from light. 6. Quench the staining by adding 5 times the original staining volume of cell culture medium containing 10% FBS. 7. Pellet cells and resuspend in pre-warmed cell culture medium. 8. Incubate cells for 10 minutes. 9. After incubation, CFSE labeled cells are ready for downstream applications or analysis.
Additional Product Notes	View more applications data for this product in our Scientific Poster Library. Watch a Scientific Poster video of this product.
Application References	1. Parish CR, <i>et al.</i> 2009. <i>Curr. Protoc. Immunol.</i> Unit4.9. 2. Miller MJ, <i>et al.</i> 2002. <i>Science</i> 296:1869. 3. Tai LH, 2013. <i>Clin Cancer Res.</i> 19:5104. PubMed 4. Svajger U, <i>et al.</i> 2014. <i>J Lukoc Biol.</i> 95:33. PubMed
(PubMed link indicates BioLegend citation)	


Product Citations

1. Soloff A, *et al.* 2017. J Appl Toxicol. 10.1002/jat.3465. [PubMed](#)
2. Zupancic E, *et al.* 2017. Journal of Controlled Release. 10.1016/j.jconrel.2017.05.014. [PubMed](#)
3. Nenasheva T, *et al.* 2017. PLoS One. 12(6):e0178983. [PubMed](#)
4. Hawila E, *et al.* 2017. Cell Rep.. 10.1016/j.celrep.2017.10.104. [PubMed](#)
5. Shifrut E *et al.* 2018. Cell. 175(7):1958-1971. [PubMed](#)
6. Page N, *et al.* 2018. Immunity. 48:937. [PubMed](#)
7. Timilshina M, *et al.* 2020. Cell Reports. 27(10):2948-2961.e7.. [PubMed](#)
8. Krueger CC, *et al.* 2019. Front Immunol. 10:1831. [PubMed](#)
9. Kwee BJ, *et al.* 2019. Sci Adv. 5:eaav6313. [PubMed](#)
10. Montel-Hagen A *et al.* 2019. Cell stem cell. 24(3):376-389. [PubMed](#)
11. Sen S, *et al.* 2018. J Immunol. 201:440. [PubMed](#)
12. Georgouli M *et al.* 2019. Cell. 176(4):757-774. [PubMed](#)
13. Barsheshet Y, *et al.* 2017. Proc Natl Acad Sci U S A. 114:6086. [PubMed](#)
14. Ershaid N, *et al.* 2019. Nat Commun. 10:4375. [PubMed](#)
15. Boland LK, *et al.* 2019. Front Immunol. 10:1080. [PubMed](#)
16. Zhou L, *et al.* 2020. Clin Cancer Res. 26:290. [PubMed](#)
17. Chen W, *et al.* 2019. Arterioscler Thromb Vasc Biol. 39:2028. [PubMed](#)
18. Rodriguez RM, *et al.* 2019. Cell Rep. 29:860. [PubMed](#)
19. Burand AJ, *et al.* 2020. Front Immunol. 11:143. [PubMed](#)
20. Wettersten Hl, *et al.* 2019. Cancer Res. 79:5048. [PubMed](#)
21. Lim J, *et al.* 2020. Sci Adv. 6:eaba1334. [PubMed](#)
22. Yang Q, *et al.* 2020. Theranostics. 6:2375. [PubMed](#)
23. Wang N, *et al.* 2020. Front Immunol. 1.765972222. [PubMed](#)
24. Sung J, *et al.* 2015. J Infect Dis. 212: 258 - 263. [PubMed](#)
25. Bonaccorsi-Riani E, *et al.* 2015. PLoS One. 10: 0136106. [PubMed](#)
26. Onodera T, *et al.* 2015. Sci Rep. 5:16801. [PubMed](#)
27. Ward D, *et al.* 2016. Haematologica. 101: 286 - 296. [PubMed](#)
28. Mercer F, *et al.* 2016. PLoS Negl Trop Dis. 10: 0004913. [PubMed](#)
29. Rosnagl S, *et al.* 2016. PLoS Biol. 14: 1002562. [PubMed](#)
30. Wei C, *et al.* 2016. Cell Death Dis. 7:e2489. [PubMed](#)
31. Just S, *et al.* 2016. Sci Rep. 6:39796. [PubMed](#)
32. Beghelli D, *et al.* 2017. Oxid Med Cell Longev. 10.1155/2017/7468064. [PubMed](#)
33. Holokai L, *et al.* 2020. Cancers (Basel). 12:00. [PubMed](#)
34. Chang T, *et al.* 2020. Aging (Albany NY). 12:21147. [PubMed](#)
35. Lv M, *et al.* 2020. Cell Res. 30:966. [PubMed](#)
36. Luo Q, *et al.* 2020. Cancer Sci. 111:4000. [PubMed](#)
37. Codo AC, *et al.* 2020. Cell Metab. 32:437. [PubMed](#)
38. Rennie K, *et al.* 2020. Clin Cancer Res. 26:5019. [PubMed](#)
39. Boyt DT, *et al.* 2020. J R Soc Interface. 17:20190815. [PubMed](#)
40. Wang Y, *et al.* 2021. Sci Rep. 1.429861111. [PubMed](#)
41. Fassler M, *et al.* 2021. J Neuroinflammation. 18:19. [PubMed](#)
42. Di Buduo CA, *et al.* 2021. eLife. 10:00. [PubMed](#)

Antigen Details

Biology Area	Cell Biology, Cell Proliferation and Viability, Neuroscience
Antigen References	1. Parish CR, <i>et al.</i> 2009. <i>Curr. Protoc. Immunol.</i> Unit4.9. 2. Lyons AB, 2000. <i>J. Immunol. Methods</i> 243:147.
Gene ID	NA

Product Data



Human peripheral blood mononuclear cells were stained with CFSE Cell Division Tracking Kit, and then stimulated with (filled histogram) or without (open histogram) PHA for 5 days. On day 5, cells were harvested and the CFSE fluorescent staining was analyzed by flow cytometry.

use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587